The Effect of Acetylcholinesterase Inhibitors on Smoking Behavior
Overview
- Phase
- Phase 2
- Intervention
- Placebo
- Conditions
- Smoking
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Change From Baseline in True Positives on the 3-Back Level of the Letter-N-Back Neurocognitive Task at Day 28 (i.e., Week 4)
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The objective of this proof-of-concept pilot study is to evaluate Donepezil HCL (Aricept) for side effects and effects on smoking behavior and performance on neurocognitive tasks in a population of dependent smokers.
Detailed Description
Nicotine dependence is a major public health problem and currently available treatments are ineffective for the majority of smokers. Thus, there is a need to develop and test novel medications to assist smokers to quit smoking. This pilot feasibility study examined: (1) tolerability and medication adherence, and (2) the effects of donepezil versus placebo on smoking behavior and cognitive performance in non-treatment seeking smokers. We predicted that 4 weeks of donepezil would improve working memory at the highest task difficulty level and sustained attention. Because participants in this study were not trying to quit, change in smoking behavior was a secondary outcome.
Investigators
Eligibility Criteria
Inclusion Criteria
- •30 smokers ages 18-50 who have smoked at least 10 cigarettes per day for the past 6 months, will be eligible to participate. They must be able to provide informed consent.
Exclusion Criteria
- •Smoking Behavior:
- •Current enrollment or plans to enroll in a smoking cessation program, or use other smoking cessation medications in the next 2 months.
- •Provide a CO reading less than 10 ppm at medical screening.
- •Participants who roll their own cigarettes.
- •Regular use of chewing tobacco or snus.
- •Alcohol/Drugs 1) History of substance abuse and/or currently receiving treatment for substance abuse (e.g. alcohol, opioids, cocaine, marijuana, or stimulants). 2) Current alcohol consumption that exceeds 25 standard drinks/week. 3) Providing a breath alcohol concentration (BrAC) reading of greater than or equal to 0.01 at medical screen, baseline, or testing sessions.
- •Women who are pregnant, planning a pregnancy, or lactating; all female subjects shall undergo a urine pregnancy test prior to enrollment and must agree in writing to use an approved method of contraception.
- •Lifetime history or current diagnosis of psychosis, bipolar disorder, anxiety disorder, or schizophrenia, as identified by the MINI. Individuals with a past history of depression are eligible as long as their major depression episode was more than 6 months ago.
- •Serious or unstable disease within the past 6 months i.e. heart disease, liver/kidney failure)
- •Other medical conditions such as peptic ulcer disease; beign prostatic hypertrophy or bladder outflow problems; asthma or chronic obstructive pulmonary disease.
Arms & Interventions
Placebo
Participants are instructed to take one placebo pill every night before going to bed with a glass of water for 28 days.
Intervention: Placebo
Donepezil
Participants are instructed to take one 5mg pill (donepezil HCL \[Aricept®\]) every night before going to bed with a glass of water for 28 days.
Intervention: Donepezil
Outcomes
Primary Outcomes
Change From Baseline in True Positives on the 3-Back Level of the Letter-N-Back Neurocognitive Task at Day 28 (i.e., Week 4)
Time Frame: Baseline and Day 28
Neurocognitive task performance was assessed during baseline and each testing day (Day 7, 14, 21, and 28) using computerized tasks. Working memory was assessed with the Letter-N-back task.
Change From Baseline in Discriminability on the Penn Continuous Performance Neurocognitive Task at Day 28 (i.e., Week 4)
Time Frame: Baseline and Day 28
Sustained attention was assessed with the Penn Continuous Performance Task (P-CPT). The primary outcome measure was the change from Baseline in discriminability (score) on the P-CPT at Day 28. The discriminability score is the mathematical difference between the total correct (i.e., true positives and correct non-responses) and incorrect (i.e., errors of commission and omission) responses to a series of stimuli presented during the P-CPT. The unit of measure is number of correct responses less the number of incorrect responses. A higher discriminability score at a single time point indicates a better performance on the P-CPT. A positive change in discriminability score between Baseline and Day 28 indicates improved performance over time. In its purest mathematical sense, the discriminability measure is a difference of difference scores and therefore is without scale limits, that is, there are no minimum or maximum values one could theoretically obtain.
Secondary Outcomes
- Change From Baseline in Smoking Behavior (i.e., Cigarettes Per Day) at Day 28 (i.e., Week 4)(Baseline and Day 28)
- Summary Side Effect Score at Day 28 (i.e., Week 4)(Day 28)